ArticleCureus2026
Adalimumab-Induced Pyodermatitis-Pyostomatitis Vegetans (PPV) in Ulcerative Colitis: A Rare Dermatological Dilemma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC), a chronic inflammatory disease affecting the rectum and colon, is commonly managed using immunosuppressants and biologics, including adalimumab. However, adalimumab administration can lead to dermatological complications, notably pyostomatitis vegetans, in UC patients. This study presents a unique case of pyostomatitis vegetans that developed in a UC patient following initiation of adalimumab therapy. The primary challenge lies in accurately differentiating between adalimumab-induced pyostomatitis vegetans and the dermatological manifestations associated with UC. Precise identification of the origin of pyostomatitis vegetans is crucial for appropriate clinical intervention. We report an exceptional case involving an 82-year-old female patient who presented with rectal discharge and a deteriorating overall condition. She had a prior diagnosis of UC and subsequently developed pyostomatitis vegetans after commencing adalimumab therapy. Treatment with adalimumab was discontinued in favor of topical corticosteroid administration, resulting in favorable outcomes. This study emphasizes the rarity of pyostomatitis vegetans, particularly in the context of adalimumab usage, underscoring the critical need for heightened vigilance in the clinical management of such occurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.